← Back to Clinical Trials
Recruiting NCT04528446

The Impact of Glomerular Disorders on Bone Quality and Strength

Trial Parameters

Condition Glomerular Disease
Sponsor Columbia University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 270
Sex ALL
Min Age 5 Years
Max Age 55 Years
Start Date 2019-06-14
Completion 2024-12
Interventions
Dual-energy X-ray absorptiometryHigh Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)Blood draw and Urine collection

Brief Summary

The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.

Eligibility Criteria

Inclusion Criteria for participants with glomerular disease: 1. CureGN participant or CureGN Eligible CureGN eligible is defined as having a diagnosis of Glomerulonephropathy (GN). Patients would otherwise be enrolled in be in CureGN study, except for lacking a minor entry criteria, such as: 1. First diagnostic kidney biopsy within 5 years of CureGN study enrollment 2. Access to first kidney biopsy report and/or slides or not being interested in study participation. 2. Males or females 5 to 55 years (premenopausal for women) 3. Females must have a negative urine/serum pregnancy test 4. Stable doses of nutritional vitamin D or active vitamin D therapy for at least 3 months before enrollment ((if on either form of Vitamin D) 5. Consent/Parental/guardian permission (informed consent) and if appropriate, child assent Exclusion Criteria for all participants 1. Chronic Dialysis 2. Solid organ transplantation 3. Lower extremity amputations or non-ambulatory 4. Malignancy requiring chemotherap

Related Trials